Prof. Dr. Wolfgang W. Schamel

Focus of research

• Molecular mechanisms of T cell activation
• Immunotherapy against cancer
• Optogenetics

CV

• since 2024 Speaker of the Excellencecluster BIOSS since
• 2024 Co-founder and Co-director of the EU PhD programme EURIdoc since
• 2019 Vice-director of the Institute for Biologie III
• since 2010 Full Professor for Immunology
• 2008–2010 Group Leader, Max Planck Institute for Immunobiology, Freiburg
• 2002–2008 Emmy Noether Group Leader, Max Planck Institute for Immunobiology, Freiburg
• 2000–2002 Postdoc at the Centro de Biologia Molecular „Severo Ochoa“, Madrid, Spain
• 1995–1999 PhD thesis in Molecular Immunology, University Freiburg
• 1988–1994 Diploma studies in Biochemistry, Free University Berlin and Weizmann Institute, Rehovot, Israel

Selected publicaionts

• Minguet S, Maus MV, Schamel WW (2024) Practice makes the master: from TCR fundamental research to innovative chimeric antigen receptor design. Nat Rev Immunol accepted
• Herr L, Fiala G, Sagar, int. al, Schamel WW (2024) Kidins220 and Aiolos promote thymic iNKT cell development by reducing TCR signals. Sci Adv. 10: eadj2802
• Velasco Cárdenas R, Brandl S, int. al, Schamel WW* & Minguet S* (2023) Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol 24: 2135–2149.  * co-last authors
• Idstein V, Ehret A, Yousefi O & Schamel WW (2023) Engineering of an Optogenetic T Cell Receptor Compatible with Fluorescence-Based Readouts. ACS Synth Biol 12: 2857–2864.
• Yousefi OS, Ruggieri M, Idstein V, int. al, Köhn M, Weber W, Timmer J, Schamel WW (2021) Cross-TCR antagonism revealed by optogenetically tuning the half-life of the TCR ligand binding. Int J Mol Sci 22: 4920